Benvenue Medical is a technology company.
Benvenue Medical has raised $139.0M across 5 funding rounds.
Benvenue Medical has raised $139.0M in total across 5 funding rounds.
Benvenue Medical is a medical technology company founded in 2004 that designs, manufactures, and markets minimally invasive spinal implants and systems, such as expandable interbody fusion devices like the Luna XD and Orbit Articulating Discectomy System, aimed at treating conditions including vertebral compression fractures (VCF) and degenerative disc disease.[1][2][3][4] It serves spine surgeons, hospitals, and surgical centers by solving problems associated with traditional open spine surgery, such as prolonged recovery times and tissue damage, through techniques that preserve anatomy, reduce surgery duration, and enable posterior minimally invasive access (MIS).[1][3][4] The company raised between $207M and $269M before being acquired by Spinal Elements around 2021, with reported 2023 revenue of $21M and about 23-26 employees based in Santa Clara, California.[1][2][4]
Benvenue Medical was founded in 2004 by Laurent Schaller, with early leadership including Robert Weigle as CEO, focusing on next-generation minimally invasive spine repair technologies combining expandable implants with novel delivery instruments.[2][5] The idea emerged from a need to advance spine therapies beyond traditional methods, starting with the Kiva VCF Treatment System for vertebral compression fractures, which gained FDA clearance and positioned the company as an innovator in the space.[1][3] Key pivotal moments included multiple funding rounds totaling over $200M from investors like CRG Partners, the acquisition of Kiva technology, and awards such as the 2019 Spine Technology Award for the Luna 3D Interbody Fusion System, culminating in its acquisition by Spinal Elements in 2021 to integrate its Luna XD and Orbit products into a broader MIS platform.[2][3][4]
Benvenue rides the trend toward minimally invasive spine surgery (MISS), driven by rising demand for faster recovery, lower costs, and outpatient procedures amid an aging population and increasing spinal disorders like degenerative disc disease.[1][4] Timing aligns with market forces favoring anatomy-conserving tech over open surgery, enabling shifts to ASCs and competing with firms like Spineology or HydroCision in a sector projected for growth via biologics and advanced implants.[1][4] Its technologies influence the ecosystem by partnering with physicians to standardize less invasive protocols, boosting adoption of expandable implants and contributing to Spinal Elements' MIS portfolio, which pushes industry boundaries in procedural efficiency.[3][4]
Post-acquisition, Benvenue's assets are relaunched under Spinal Elements with manufacturing ramp-up, positioning Luna XD and Orbit for expanded MIS adoption in hospitals and ASCs.[4] Trends like AI-assisted surgery planning and biologics integration will shape its path, potentially amplifying influence through broader commercialization and new clearances. As Spinal Elements advances these "fundamental shifts" in spine care, Benvenue's legacy in expandable tech cements its role in enduring, patient-centric spinal repair.[4]
Benvenue Medical has raised $139.0M in total across 5 funding rounds.
Benvenue Medical's investors include Accel, ICONIQ Capital, InterWest, Madrona Ventures, Versant Ventures, Wildcat Ventures, Dino Vendetti.
Benvenue Medical has raised $139.0M across 5 funding rounds. Most recently, it raised $23.0M Series F in January 2016.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2016 | $23.0M Series F | Accel, ICONIQ Capital, InterWest, Madrona Ventures, Versant Ventures, Wildcat Ventures, Dino Vendetti | |
| Jun 1, 2014 | $40.0M Series E | Accel, ICONIQ Capital, InterWest, Madrona Ventures, Versant Ventures, Wildcat Ventures, Dino Vendetti | |
| Jun 1, 2012 | $25.0M Series D | Versant Ventures | |
| Apr 1, 2011 | $36.0M Series C | Versant Ventures | |
| Jan 1, 2008 | $15.0M Series B | Versant Ventures |